Home > Back to Publisher > Report Information

Growth Factors (Blood And Tissue)

Global Industry Analysts
October 1, 2008
576 Pages - SKU: GJOB2056532

Abstract Table of Contents Related Reports

Countries covered: Global

This report analyzes the worldwide markets for Growth Factors (Blood And Tissue) in Millions of US$. The major product segments analyzed are Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 90 companies including many key and niche players worldwide such as Amgen, Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Alseres Pharmaceuticals, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., FzioMed Inc., GeneMedix PLC, Insmed Inc., Johnson & Johnson, Janssen-Ortho, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability And Reporting Limitations; Disclaimers; Quantitative Techniques & Analytics; Erythropoietins
II. EXECUTIVE SUMMARY: 1. Introduction; Growth Factors: A Preface; Recent Trends & Developments; 2. Market Overview; Analysis by Region; Analysis by Growth Factor Type; Market Comparison of Erythropoietin-Based Drugs in America and European Union:; 3. Market Dynamics; Dethroning the Leaders; CDER- A Regulatory Review Authority for Growth Factors; 4. Outlook; Innovative Delivery System Shows Potential for Accelerating Use of Growth; Copaxone Finds Novel Applications; 5. Industry Issues; Development of Cost Effective Methods - Need of the Hour; 6. Competitive Trends; RegeneRx Focuses on Wound Healing Market; 7. Growth Factors - An Overview; Blood Growth Factors; Darbepoetin; Table 2: World Market for Erythropoietins (2000-2010): Geographic Regions Ranked by CAGR - Europe, US, Japan and Rest of World (includes corresponding Graph/Chart); Macrophage Colony Stimulating Factor (M-CSF); Types of Interferons; Types of Interferons; Table 4: World Market for Interferons as Blood Growth Factors (2000-2010): Geographic Regions Ranked by CAGR - US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart); Interleukins; Types of Interleukins; Table 5: World Market for Interleukins as Blood Growth Factors (2000-2010): Geographic Regions Ranked by CAGR - Europe, Japan, US, and Rest of World (includes corresponding Graph/Chart); Vascular Endothelial Growth Factor (VEGF); Platelet - Derived Growth Factors in Wound Healing; Angiogenesis: Their Role in Wound Healing; Growth Factors: Application by Compound and Supplier; 8. Research and Development Highlights; Maxygen Updates on Factor VII Program; Cytokines and GM-CSF Found to be Closely Interlinked; rG-CSF- Their Influence on Preterm Infants with Sepsis; Cole Eye Institute Offers TIMP-3 Mechanism for Preventing Abnormal Growth of Blood; Orcel™ Exhibits High Growth Factor for Wound Healing and Cardiovascular; Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates Wound Healing; Granulocyte Colony Stimulating Factor Finds Application in Treating Neonates; Novel Set of Human Cytokines Unveiled; Neurotrophic Growth Factor Primarily Responsible for Loss of Vision; Genentech Inc Unveils Molecule for Stimulating Growth of Blood Vessels; Regeneron Discovers Angiopoietins Targeted at Blood Vessel Growth and Repair; Axokine® Yields Favorable Results Against Obesity; 10. Recent Industry Activity; Pfizer Inks Exclusive Global Licensing Agreement with Scil Technology; Fraunhofer Institute Introduces First Interferon Beta 1a to Treat Multiple Sclerosis; Bayer Launches US Pharmaceuticals Subsidiary; Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals; Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric Patients; Hospira Receives EC Approval on Retacrit; CytoPharm Acquires Low-Dose Interferon License from Amarillo Biosciences; Mayne and Pliva to End Collaboration on Erythropoietin Development; AnGes MG Enters Into An Agreement with Vical; GeneMedix Restructures Business; DPI Receives Approvals for Erythropoietin in Three New Markets; Dragon Pharmaceuticals to Construct New Production Facility; 11. Strategic Corporate Developments in Recent Past; AME Enters into Third Collaboration with Eli Lilly and Company; Dragon Pharmaceuticals Bags Market Approval from Chinese SDA; ViaCell Acquires Cerebrotec; GeneMedix Bags Chinese SDA Approval; NTB Enters into BioInformatics Outsourcing Agreement with HSC; 12. Product Launches in Recent Past; Wockhardt Introduces Wepox Recombinant Erythropoietin Drug; 13. Focus on Select Global Players; Amgen, Inc. (USA); Alseres Pharmaceuticals, Inc. (USA); GeneMedix Plc. (UK); Janssen-Ortho Inc. (Canada); NsGene A/S (Denmark); Chugai Pharmaceutical Co. Ltd. (Japan); Scil Proteins GmbH (Germany); 14. Global Market Perspective; Table 7: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart); Table 8: World Long-term Projections for Growth Factors (Blood and Tissue) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 9: World 10-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 10: World Recent Past, Current & Future Analysis for Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart); Table 11: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart); Table 12: World Long-term Projections for Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 13: World Long-term Projections for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 14: World 10-Year Perspective for Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 15: World 10-Year Perspective for Blood Growth Factors by Type - Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 16: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart); Table 17: World Long-term Projections for Erythropoietins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 18: World 10-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 19: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart); Table 20: World Long-term Projections for Colony Stimulating Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 21: World 10-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 22: World Recent Past, Current & Future Analysis for Interferons as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart); Table 23: World Long-term Projections for Interferons as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 24: World 10-Year Perspective for Interferons as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 25: World Recent Past, Current & Future Analysis for Interleukins as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart); Table 26: World Long-term Projections for Interleukins as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 27: World 10-Year Perspective for Interleukins as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 28: World Recent Past, Current & Future Analysis for Tissue Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart); Table 29: World Long-term Projections for Tissue Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 30: World 10-Year Perspective for Tissue Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
III. MARKET: 1. The United States; A. Market Analysis; Recent Industry Activity; Strategic Corporate Developments in Recent Past; Product Launches in Recent Past; Key Players; B. Market Analytics; Table 32: US Long-term Projections for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 33: US 10-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 2. Japan; A. Market Analysis; dustry Activity; B. Market Analytics; Table 35: Japanese Long-term Projections for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 36: Japanese 10-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 3. Europe; A. Market Analysis; Strategic Developments in Recent Past; Product Launch in Recent Past; B. Market Analytics; Table 37: European Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart); Table 38: European Long-term Projections for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 39: European 10-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4. Rest of World; A. Market Analysis; Interferon; Strategic Developments in Recent Past; Product Launches in Recent Past; Key Players; B. Market Analytics; Table 41: Rest of World Long-term Projections for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 42: Rest of World 10-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE: Total Companies Profiled: 90 (including Divisions/Subsidiaries - 101); Region/Country Players; The United States 55; Canada 3; Japan5; Europe 24; Germany 11; The United Kingdom2; Rest of Europe11; Asia-Pacific (Excluding Japan) 14

More Global Research & Development Reports

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition by Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, ...

Global Biotechnology by IBISWorld
Global Biotechnology Biotechnology is the application of science and technology to living organisms as well as parts, products and models thereof, to alter living or non-living ...

Global Protein Therapeutics Market Forecast to 2015 by RNCOS
Protein-based therapies have found a prominent place in the biopharmaceutical industry since the launch of human insulin product. They have become one of the most ...

Global Pharmaceuticals, Biotechnology & Life Sciences by MarketLine
Introduction Global Pharmaceuticals, Biotechnology & Life Sciences industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2006-10, and forecast to ...

Biotechnology by Global Industry Analysts
The global outlook series on Biotechnology provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report offers a bird’s ...

See all reports like this >>

Growth Factors (Blood And Tissue)

Share this report

Other tasks

Research Assistance

Related Markets

Research & Development Reports

Free Alert Me service